Oxycodonhydrochlorid Puren (Oxycodone Hydrochloride)

Oxycodone Hydrochloride, the active ingredient in Oxycodonhydrochlorid Puren, is an opioid analgesic presented as a [strength]/[form] for oral use. It is employed in the management of moderate to severe pain, particularly when other analgesics are insufficient, and is prescribed for adult patients.

GNH USA supplies Oxycodonhydrochlorid Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxycodone Hydrochloride is an opioid that acts on the central nervous system to relieve pain across several conditions. - Acute postoperative pain: Provides strong analgesia during the immediate recovery period after surgery. - Cancer‑related pain: Helps control persistent pain associated with malignant disease. - Severe chronic non‑cancer pain: Reduces pain intensity when other treatments have failed. - Traumatic injury pain: Alleviates pain from major fractures or severe tissue damage. - Palliative care pain: Improves comfort for patients in end‑of‑life settings.

Oxycodone Hydrochloride may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects: - Constipation: Reduced gastrointestinal motility leading to hard stools. - Nausea and vomiting: Stomach upset often occurring at treatment initiation. - Drowsiness: Sedation that may impair alertness. - Dry mouth: Decreased salivary flow causing oral discomfort. - Dizziness: Light‑headed sensation, especially when standing quickly. - Itching (pruritus): Mild skin irritation without rash.

Serious or Rare Side Effects: - Respiratory depression: Slowed breathing that can be fatal. - Severe hypotension: Marked drop in blood pressure causing fainting. - Opioid use disorder: Development of dependence or addiction. - Seizures: Uncommon convulsive episodes. - Anaphylaxis: Acute allergic reaction with airway compromise. - adrenal insufficiency: Hormonal imbalance affecting stress response.

When prescribing Oxycodone Hydrochloride, clinicians should consider several safety measures to minimise risk. - Assess pain severity and prior opioid exposure: Determines appropriate starting dose. - Evaluate respiratory function: Patients with compromised breathing need close monitoring. - Review concomitant CNS depressants: Increases risk of sedation and respiratory depression. - Monitor for signs of dependence: Look for cravings, tolerance, or withdrawal. - Adjust dose in renal or hepatic impairment: Impaired metabolism may raise drug levels. - Store at ambient temperature: keep the product in its original packaging, protected from moisture and direct sunlight.

Oxyhydro­phyl­    g    

---

---   t  

   t